ACADIA Pharmaceuticals (ACAD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

ACADIA Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$27.67+0.13(<0.01%)Market open

Market Cap

$4.68B

P/E

12.3x

P/S

4.1x

P/B

3.6x

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

How this company scores

GoodMetricSide Score: 72/100

Strongest: Profitability (21/25); weakest: Cash & Earnings Quality (15/25).

Profitability21/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality15/25

Strengths

High ROERising earningsInterest easily coveredCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 12.3x5y range 9.6x – 88.0x

Currently near its 9-quarter median.

P/S · 4.1x5y range 0.0x – 8.0x

Currently above its 20-quarter median.

P/B · 3.6x5y range 0.0x – 8.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 67.9% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Share Dilution

Watch

Shares outstanding rose 3.4% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $4.68B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.14B
Q. Revenue: $307.96M
TTM EBITDA: $86.37M
TTM Op. Income: $86.37M
Q. Op. Income: $37.84M
TTM Net Income: $380.48M
Q. Net Income: $31.50M
EPS: $0.18
Shares Out.: $171.60M

$1.14B in TTM revenue grew 11.8% YoY, reaching $307.96M last quarter. TTM EBITDA of $86.37M and TTM operating income of $86.37M show growth is flowing through to the bottom line. TTM net income of $380.48M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 90.8%
EBITDA Margin: 12.3%
Op. Margin: 12.3%
Net Margin: 10.2%

Op. margin of 12.3% is up 0.0% YoY — cost efficiency is improving. Net margin at 10.2% and gross margin of 90.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 0% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 12.3x
P/S Ratio: 4.1x
P/B Ratio: 3.6x

At 12.3x P/E, the stock trades below typical market levels. P/S of 4.1x and P/B of 3.6x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 24% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.74B
Cash: $384.99M
Long-Term Debt: N/A
Book Value: $1.31B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $100.78M
TTM Free Cash Flow: $145.63M
FCF Margin: 12.8%
FCF / Net Income: 0.4

TTM FCF of $145.63M on $100.78M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.